What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List
US neurologists in Spherix’s in-house physician network complete a patient chart audit of over 600 patients with gMG. Exton, PA, August 10, 2023 – In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia Gravis not only illuminates critical aspects of patients’ presentation, diagnosis, and management […]
How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression
According to Spherix Global Insights first market landscape study on Amyotrophic Lateral Sclerosis (ALS), general neurologists lack awareness of therapies in development for ALS. EXTON, Pa., August 2, 2023 – A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease progression in the […]
Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?
According to Spherix Global Insights, U.S. neurologists are largely satisfied with current treatment choices in the RMS market, but opportunities remain. Exton, PA, August 1, 2023 – Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis market continues to offer drug developers opportunities to break in – if their new assets offer […]
At Eighteen Months Post-Launch, Impel’s Trudhesa Has Struggled to Keep Up with Pfizer’s Nurtec ODT and AbbVie’s Ubrelvy, According to Spherix Global Insights
Use of Trudhesa as an acute migraine treatment is on par with the more-established Reyvow, though future projections have it exceeding the Eli Lilly offering. Exton, PA., April 14, 2023 – Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study tracking the launch of […]
Imaging required to monitor effects of new Alzheimer’s drug could inhibit its uptake
Although providers are optimistic about the potential of a new treatment for Alzheimer’s, some are concerned that the burden of monitoring the drug’s effect on patients could limit its uptake. In January 2023, Eisai/Biogen’s Leqembi—a drug shown to reduce clinical decline by up to 27% in patients with Alzheimer’s—was given accelerated approval by the U.S. Food and Drug […]
Eisai’s Alzheimer’s drug Leqembi gaining ground with US neurologists, but most waiting on full approval: Spherix
U.S. neurologists are “cautiously optimistic” about using Eisai’s Leqembi in Alzheimer’s disease as concerns about safety and the need for the FDA’s full green light for the drug remain high barriers to uptake. That’s according to a new survey and report out by drug launch analyst Spherix Global Insights, which in March asked 73 neurologists working in […]
At Fifteen Months Post-Launch, AbbVie’s Qulipta Outperforms Pfizer’s Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights
Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands’ use on par. Exton, PA., March 16, 2023 – Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch of AbbVie’s Qulipta for the preventive treatment […]
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide Differentiation amongst these pipeline agents will hinge on ease of access, easy-to-use companion diagnostics, and safety EXTON, Pa., July 2022 – Despite multiple high-profile trial failures in early Alzheimer’s disease […]
Biohaven’s Nurtec ODT and AbbVie’s Qulipta Emerging as the Top Two Contenders in the Preventive Migraine Space, According to Spherix Global Insights
Growth of newer market entrants resulting in relatively flat projected share for Eli Lilly’s Emgality, Teva’s Ajovy, and Amgen’s Aimovig EXTON, Pa., June 10, 2022 /PRNewswire – According to the latest deep dive report included in Spherix’s Launch Dynamix™: Qulipta for Migraine Prevention (US) service, surveyed neurologists and migraine specialists report high satisfaction with AbbVie’s Qulipta […]
Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada
From: Multiple Sclerosis News Today By: Marisa Wexler MS Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS treatments in Canada by […]
